Medindia

X

Optimer Pharmaceuticals Announces Presentations of Data From the Fidaxomicin Phase 3 Trials at ECCMID

Wednesday, April 7, 2010 Research News J E 4
Advertisement


SAN DIEGO, April 6 Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced that data from the fidaxomicin Phase 3 clinical studies will be presented at the 20th annual European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Vienna, Austria.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090413/LA97352LOGO)

"Randomized clinical trial in Clostridium difficile infection confirms equivalent cure rate and lower recurrence rate of fidaxomicin vs. vancomycin"

Poster presenter: Derrick Crook, M.D.

Saturday, April 10, 2010 3:30pm-4:30pm Central European Summer Time (6:30am-7:30am PST)

Presentation number: LB2401

"Three simple ESCMID severity criteria predict poor cure rate and slower resolution of diarrhea in Clostridium difficile infection"

Poster presenter: Mark A. Miller, M.D.

Saturday, April 10, 2010 3:30pm-4:30pm Central European Summer Time (6:30am-7:30am PST)

Presentation number: LB2394

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infectives to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection. Optimer has reported positive top-line results from two Phase 3 trials of fidaxomicin. Pruvel(TM) is a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea. Optimer has also successfully completed two Phase 3 trials with Pruvel. Additional information can be found at http://www.optimerpharma.com.

Contacts Optimer Pharmaceuticals, Inc. Christina Donaghy, Corporate Communications Manager John D. Prunty, Chief Financial Officer & VP Finance 858-909-0736 Porter Novelli Life Sciences Jason I. Spark, Vice President 619-849-6005

SOURCE Optimer Pharmaceuticals, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Patient Enrollment Complete in Tragara Pharmaceuti...
S
BIO Ventures for Global Health Announces New Chief...